Meitav Investment House Ltd. Has $30.20 Million Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Meitav Investment House Ltd. trimmed its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 33.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,370,855 shares of the company's stock after selling 695,467 shares during the period. Meitav Investment House Ltd. owned about 0.67% of Cellebrite DI worth $30,200,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of CLBT. Pathway Financial Advisers LLC boosted its holdings in shares of Cellebrite DI by 1,583.8% during the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company's stock worth $74,000 after purchasing an additional 4,118 shares during the last quarter. Tower View Wealth Management LLC grew its stake in shares of Cellebrite DI by 1.2% during the third quarter. Tower View Wealth Management LLC now owns 130,647 shares of the company's stock valued at $2,200,000 after acquiring an additional 1,500 shares in the last quarter. Pembroke Management LTD grew its stake in shares of Cellebrite DI by 24.3% during the third quarter. Pembroke Management LTD now owns 1,908,345 shares of the company's stock valued at $32,137,000 after acquiring an additional 372,619 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Cellebrite DI by 8.3% in the third quarter. Janney Montgomery Scott LLC now owns 51,155 shares of the company's stock worth $861,000 after purchasing an additional 3,912 shares in the last quarter. Finally, Harbor Capital Advisors Inc. grew its stake in Cellebrite DI by 96.1% in the third quarter. Harbor Capital Advisors Inc. now owns 95,351 shares of the company's stock worth $1,606,000 after purchasing an additional 46,727 shares in the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Craig Hallum lifted their target price on Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Lake Street Capital upped their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price target on shares of Cellebrite DI in a report on Friday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $23.43.

Cellebrite DI Stock Performance

Cellebrite DI stock traded up $0.05 during trading hours on Friday, hitting $19.12. 3,548,554 shares of the stock were exchanged, compared to its average volume of 2,077,086. Cellebrite DI Ltd. has a 12 month low of $10.24 and a 12 month high of $26.30. The business's 50-day moving average is $22.55 and its two-hundred day moving average is $19.33. The stock has a market capitalization of $3.94 billion, a P/E ratio of -13.76, a P/E/G ratio of 4.40 and a beta of 1.47.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, equities analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.